Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 6/20 | 0.54 |
| ▸ | HTR3A | P46098 | 2/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14810412 | 0.92 | HTR4 (0.59) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5316552 | 0.85 | HTR4 (0.47) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL14810317 | 0.83 | HTR4 (0.48) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7751844 | 0.81 | HTR4 (0.50) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL17978230 | 0.81 | HTR4 (0.50) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7333211 | 0.81 | HTR4 (0.46) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5318150 | 0.80 | HTR4 (0.53) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL8509459 | 0.80 | HTR4 (0.52) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL17978247 | 0.79 | HTR4 (0.53) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL17978151 | 0.78 | HTR4 (0.52) | HTR4HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636335-B2 | Heteroaryl compounds as 5-HT4 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-05-02 | — | — | US | disclosed |
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-08 | — | — | US | disclosed |
| US-9079894-B2 | Heteroaryl compounds as 5-HT4 receptor ligands | SUVEN LIFE SCIENCES LTD (IN) | 2015-07-14 | — | — | US | disclosed |
| EP-2758394-B1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-02-18 | — | — | EP | disclosed |
| EP-2758394-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2014-07-30 | — | — | EP | disclosed |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-07-03 | — | — | US | disclosed |
| CN-103380131-A | Heteroaryl compounds as 5-ht4 receptor ligands | SUVEN LIFE SCIENCES LTD | 2013-10-30 | — | — | CN | disclosed |
| WO-2013042135-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | HTR4 1/4885HTR3A 6/4885HTR3E 12/4885 |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | HTR4 1/4885HTR3A 6/4885HTR3E 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.